share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/13 20:17

Moomoo AI 已提取核心訊息

Cingulate Inc. reported Q2 2024 financial results with a net loss of $3.2 million, down from $6.6 million in Q2 2023, as research and development expenses decreased 57.8% to $1.9 million. The company ended the quarter with $0.4 million in cash and cash equivalents. Revenue remains at zero as the company continues product development activities.Research and development costs declined primarily due to reduced clinical trial activity for CTx-1301, as enrollment in two Phase 3 pediatric studies was completed in late 2023. General and administrative expenses decreased 30.5% to $1.3 million, driven by lower headcount and cost containment measures including salary reductions. The company is targeting an NDA submission for CTx-1301 in the first half of 2025.Management estimates approximately $12-13 million in additional capital is needed to achieve the CTx-1301 NDA filing timeline. The company is actively seeking a strategic pharmaceutical partnership and exploring various financing options, having raised funds through warrant exercises and stock sales in Q2. Subsequent to quarter end, Cingulate received $1.6 million from a warrant inducement transaction that closed July 1, 2024.
Cingulate Inc. reported Q2 2024 financial results with a net loss of $3.2 million, down from $6.6 million in Q2 2023, as research and development expenses decreased 57.8% to $1.9 million. The company ended the quarter with $0.4 million in cash and cash equivalents. Revenue remains at zero as the company continues product development activities.Research and development costs declined primarily due to reduced clinical trial activity for CTx-1301, as enrollment in two Phase 3 pediatric studies was completed in late 2023. General and administrative expenses decreased 30.5% to $1.3 million, driven by lower headcount and cost containment measures including salary reductions. The company is targeting an NDA submission for CTx-1301 in the first half of 2025.Management estimates approximately $12-13 million in additional capital is needed to achieve the CTx-1301 NDA filing timeline. The company is actively seeking a strategic pharmaceutical partnership and exploring various financing options, having raised funds through warrant exercises and stock sales in Q2. Subsequent to quarter end, Cingulate received $1.6 million from a warrant inducement transaction that closed July 1, 2024.
Cingulate Inc. 公佈了2024年第二季度財務結果，淨虧損爲320萬美元，較2023年第二季度的660萬美元有所減少，因爲研發費用下降了57.8%，降至190萬美元。該公司在季度末的現金及現金等價物爲40萬美元。營業收入保持在零，因爲公司仍在進行產品開發活動。研發成本下降主要是由於CTx-1301的臨牀試驗活動減少，因爲兩個第三期兒童研究的入組在2023年末完成。一般及管理費用下降了30.5%，降至130萬美元，這主要是由於員工人數減少和包括薪資削減在內的成本控制措施。公司計劃在2025年上半年提交CTx-1301的新藥申請（NDA）。管理層估計，達成CTx-1301新藥申請提交時間表大約需要1200-1300萬美元的額外資金。公司正在積極尋求戰略藥品合作伙伴關係，並探索各種融資選項，在第二季度通過認股權證行使和股票銷售籌集了資金。在季度結束後，Cingulate 於2024年7月1日通過一項認股權證誘導交易收到了160萬美元。
Cingulate Inc. 公佈了2024年第二季度財務結果，淨虧損爲320萬美元，較2023年第二季度的660萬美元有所減少，因爲研發費用下降了57.8%，降至190萬美元。該公司在季度末的現金及現金等價物爲40萬美元。營業收入保持在零，因爲公司仍在進行產品開發活動。研發成本下降主要是由於CTx-1301的臨牀試驗活動減少，因爲兩個第三期兒童研究的入組在2023年末完成。一般及管理費用下降了30.5%，降至130萬美元，這主要是由於員工人數減少和包括薪資削減在內的成本控制措施。公司計劃在2025年上半年提交CTx-1301的新藥申請（NDA）。管理層估計，達成CTx-1301新藥申請提交時間表大約需要1200-1300萬美元的額外資金。公司正在積極尋求戰略藥品合作伙伴關係，並探索各種融資選項，在第二季度通過認股權證行使和股票銷售籌集了資金。在季度結束後，Cingulate 於2024年7月1日通過一項認股權證誘導交易收到了160萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。